We are excited to announce new featured audiences at China Focus@Europe Hamburg! Apply for company presentation (Pitch and Match) now and pitch your latest innovations to potential investors and partners.
Why present at @China Focus What can you get Presentation fee
Featured Audiences
Jiangsu Hengrui Medicine: a leading biopharmaceutical company based in China with annual net sales of over $2.5 billion in 2018, and has over 130 ongoing clinical trials. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan, and Germany.
News: June 17, 2019 – Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 in China. Hengrui will pay Mycovia $7.5 million in development funding, and commits to $9 million in development milestones and up to $92 million in potential sales milestones.
Representatives:
Senior Manager of BD
Senior Director and China Head of Business Develop
BioSense was established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The organization’s mission is to bridge the gap between undercapitalized biopharmaceutical projects, companies, and investors.
News: April 16, 2019 – BioSense acquired Greater China rights of RX-3117 from Rexahn in a deal potentially worth $226 million.
Representatives:
CEO and President
Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small-molecule drugs to treat liver diseases and cancers. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.
News: Jun 24, 2019 – GENFIT and Terns Pharmaceuticals announce a $228MM strategic partnership to develop and commercialize Elafibranor in Greater China.
Representative:
Director, Business Development and Finance
Since the company’s foundation in 2005, the Apogenix team has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. These protein therapeutics target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response, and thus have the potential to transform the treatment of oncological and malignant hematological diseases.
News: July 15, 2015 – Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China.
Representative:
VP, Business Development
